Page 22 - Read Online
P. 22
Chok Surgical strategy for huge/advanced HCC
DOWNSTAGING treatment modalities are still evolving. ALPPS will
continue to be developed and more long-term results
Both TACE and radioembolization are safe and effective will be available in the near future.
in highly selected patients. Radioembolization may
confer a survival benefit over sorafenib on advanced- DECLARATIONS
stage patients. Radioembolization is preferable to
TACE for advanced-stage patients, especially those Authors’ contributions
with macrovascular invasion, since TACE might K.S.H. Chok contributed solely to this paper.
induce liver failure. [53] However, the effectiveness of
downstaging is not conclusive, as most of the cases Financial support and sponsorship
reported were limited by poor underlying liver function. None.
EXTRAHEPATIC METASTASIS Conflicts of interest
Lung is the most common site for extrahepatic The author has no conflicts of interest with regard to
metastasis of HCC. [54] A previous study by our the study or its publication.
center reported that metastasectomy conferred a
survival benefit on HCC patients who developed lung Patient consent
metastasis after hepatectomy. [55] Overall survival Not applicable.
was compared in patients with resectable and
unresectable lung metastases and in two periods (Era Ethics approval
1: 1989-1995, Era 2: 1996-2010). The median survival Not applicable.
duration of patients with resectable and unresectable
disease was 40.4 and 7.5 months respectively (P < REFERENCES
0.0001). In Era 1, the median survival duration of
patients with resectable and unresectable disease 1. Kim DY, Han KH. Epidemiology and surveillance of hepatocellular
was 43.2 and 5.6 months respectively (P < 0.0001). carcinoma. Liver Cancer 2012;1:2-14.
The corresponding figures in Era 2 were 32.9 and 2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.
8.4 months (P < 0.0001). Survival of patients with Estimates of worldwide burden of cancer in 2008: GLOBOCAN
2008. Int J Cancer 2010;127:2893-917.
resectable disease did not differ significantly in the 3. Fan ST, Poon RT, Yeung C, Lam CM, Lo CM, Yuen WK, Ng KK, Liu
two periods but there was a significant improvement CL, Chan SC. Outcome after partial hepatectomy for hepatocellular
in survival of patients with unresectable disease in cancer within the Milan criteria. Br J Surg 2011;98:1292-300.
Era 2. Their 1-, 3- and 5-year survival rates in Era 4. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the
1 vs. Era 2 were 11% vs. 38%, 6% vs. 9%, and 3% BCLC staging classification. Semin Liver Dis 1999;19:329-38.
vs. 4%, respectively (P = 0.041). The corresponding 5. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in
figures in their counterparts were 90% vs. 86%, 80% 6. hepatocellular carcinoma. Hepatology 2002;35:519-24.
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet
vs. 46%, and 40% vs. 30%, respectively (P = 0.443). 2003;362:1907-17.
Whenever possible, metastasectomy for pulmonary 7. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging
metastases of HCC should be offered to medically fit and treatment: the BCLC update and future prospects. Semin Liver Dis
patients. 2010;30:61-74.
8. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of
CONCLUSION Hong Kong Liver Cancer staging system with treatment stratification
for patients with hepatocellular carcinoma. Gastroenterology
Although huge and advanced HCC is deadly, surgical 9. 2014;146:1691-700.e3.
Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK,
treatment in properly selected patients is still feasible Ming Lam C, Ng KK, Ching Chan S. Continuous improvement of
with acceptable risks. In recent years, there are survival outcomes of resection of hepatocellular carcinoma: a 20-year
revolutional changes in surgical techniques together experience. Ann Surg 2011;253:745-58.
with new strategies to enhance the resectability of this 10. Cauchy F, Soubrane O, Belghiti J. Liver resection for HCC:
fatal disease. Ways to increase FLR and improvements patient’s selection and controversial scenarios. Best Pract Res Clin
in surgical techniques allow more patients to benefit Gastroenterol 2014;28:881-96.
from surgical resection even in the presence of 11. Poon RT, Fan ST. Assessment of hepatic reserve for indication
of hepatic resection: how I do it. J Hepatobiliary Pancreat Surg
cirrhosis and major vascular invasion. Adjunctive use 2005;12:31-7.
of radiofrequency ablation for bilobar involvement 12. Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO, Wong J. Anterior
and selective use of metastasectomy for extrahepatic approach versus conventional approach right hepatic resection for
metastasis have been shown to be effective. Optimal large hepatocellular carcinoma: a prospective randomized controlled
Hepatoma Research ¦ Volume 3 ¦ September 03, 2017 193